 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...1516171819202122232425...858859» |
- The impact of treatment with omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab in patients with severe asthma () - Nov 5, 2024 - Abstract #APSR2024APSR_185;
There is a need to consider each case individually when introducing or changing Biologics with reference to complications, improvement in pulmonary function tests, andso on.
- || Repatha (evolocumab) / Amgen, Astellas
P4 data, Journal, Real-world evidence, Real-world: Safety and Effectiveness of Low-Density Lipoprotein Cholesterol-Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real-World, Postmarketing, Single-Arm Study. (Pubmed Central) - Nov 5, 2024
P=N/A
There is a need to consider each case individually when introducing or changing Biologics with reference to complications, improvement in pulmonary function tests, andso on. Evolocumab was well tolerated, and real-world patients with familial hypercholesterolemia and hypercholesterolemia with high risk in Japan had sustained low-density lipoprotein cholesterol reduction.
- | Repatha (evolocumab) / Amgen, Astellas
Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study. (Pubmed Central) - Nov 5, 2024
In a real-world cohort of HeFH patients, most of which were intolerant to statins, a high majority were able to achieve a ?50% reduction in LDL-C after 12?months of PCSK9 inhibitor therapy (mean reduction of approximately 59%), which is similar to clinical trial data of patients with ASCVD. A significant reduction in non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) were also observed.
- || deflazacort / Generic mfg.
Review, Journal: Deflazacort-induced Steven-Johnson syndrome: a case report and literature review (Pubmed Central) - Nov 5, 2024
A significant reduction in non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) were also observed. Complete remission of SJS was achieved after treatment with intravenous immunoglobulin (IVIG, total 1.4 g/kg), 2 doses of etanercept (0.9 mg/kg, once), subcutaneous injection and intravenous methylprednisolone (0.7 mg/(kg
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Enrollment open: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study (clinicaltrials.gov) - Nov 5, 2024
P3, N=500, Recruiting, Sponsor: American Society of Clinical Oncology
Complete remission of SJS was achieved after treatment with intravenous immunoglobulin (IVIG, total 1.4 g/kg), 2 doses of etanercept (0.9 mg/kg, once), subcutaneous injection and intravenous methylprednisolone (0.7 mg/(kg Not yet recruiting --> Recruiting
- || Tepezza (teprotumumab-trbw) / Roche, Amgen
New P1 trial: A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants (clinicaltrials.gov) - Nov 5, 2024
P1, N=44, Completed, Sponsor: Amgen
- Lonsurf (trifluridine/tipiracil) / Otsuka, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Survival Benefit of Oral Systemic Monotherapy Treatment in Heavily Pre-Treated Metastatic Colorectal Cancer: A Meta-Analysis () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3212;
Oral systemic monotherapy treatments provide significant survival benefits for heavily pre-treated mCRC, including when used in the fourth-line setting and beyond. In this meta-analysis, the improvement in mOS following active treatment versus placebo+BSC was <2 months, indicating that the increases in mOS with oral systemic monotherapies versus placebo+BSC observed in RCTs, in heavily pre-treated mCRC, are meaningful.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Cost-Effectiveness of Tezepelumab in Taiwan for Severe Asthma () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3190;
Patients who experience an exacerbations result in either a burst in OCS, an A&E visit or hospitalization, the latter resulting in the largest cost and quality of life burden. The results from the analysis show that tezepelumab is dominant and is a cost-effective treatment when compared to the other biologics.
- Siliq (brodalumab) / Bausch Health, Humira (adalimumab) / AbbVie
Induction Cost Per Responder of Brodalumab Compared With Other Biologic Therapies for Patients With Moderate to Severe Plaque Psoriasis in Canada () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3175;
The CPR was estimated as the drug acquisition costs during the induction period multiplied by the number needed to treat (NNT) for achieving PASI 75, 90, or 100 for the following treatments: adalimumab (innovator and SEB), brodalumab, bimekizumab, certolizumab pegol, etanercept (innovator and SEB), guselkumab, infliximab (innovator and SEB), ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab (innovator and SEB). These results demonstrate that brodalumab has the lowest induction CPR across all PASI outcomes compared to other biologic therapies, including SEB therapies, thus providing the best value for money for patients, prescribers, and payers.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Treatment Cost for CDK 4/6 Inhibitors for HR+/HER2- Advanced and Metastatic Breast Cancer Patients in Portugal Based on Real-World Dosing Patterns: Insights From the PORTRAIT Study () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2869;
Ribociclib reported longer treatment duration and lower monthly costs compared to other CDKi . These findings are relevant to the Portuguese public hospitals sustainability.
- Strategies of Operational Savings in an Integrated Care Clinic for Immune-Mediated Skin Diseases () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2778;
The drugs managed were mainly 29.8% omalizumab, 21.8% adalimumab, 16.8% dupilumab, 7.7% ixekizumab, 7.4% guselkumab, 4.9% ustekinumab, 4.2% secukinumab, 2.1% etanercept, 2.1% risankizumab, and 3.2% other drugs. CLIPSO generates a relevant economic impact on the appropriate prescription and scaling of biological therapies for patients with immune-mediated skin diseases.
- Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Characteristics, Treatments, and Clinical Outcomes of Patients With Ornithine Transcarbamylase Deficiency in the United States () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2663;
CLIPSO generates a relevant economic impact on the appropriate prescription and scaling of biological therapies for patients with immune-mediated skin diseases. Real-world evidence demonstrates a high symptomatic burden and HAE/crisis event rates, indicating a significant clinical burden in OTCD patients.
- TNG908 / Tango Therap, AMG 193 / Amgen
Exploring the Clinical Translation of Synthetic Lethality, PRMT5 Inhibitors in MTAP-Deleted Cancers: A Scoping Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2652;
P1/2
Real-world evidence demonstrates a high symptomatic burden and HAE/crisis event rates, indicating a significant clinical burden in OTCD patients. Notably, six oral PRMT5 inhibitors
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Comparison of Rheumatoid Arthritis Treatment Patterns Pre-, During, and Post-COVID-19 Quarantine in the United States: National Data From the TriNetX Network () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2629;
We found that use of conventional and biologic drugs for RA were hardly affected by COVID-19 when assessing patient treatment patterns in secondary data sources. Potential biases associated with the reduction in available patients during Q compared to PQ, POQ, and PC requires attention in future studies.
- Humira (adalimumab) / AbbVie
Evaluating the Effectiveness of Switching Treatments in Chronic Psoriasis: A Targeted Literature Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2628;
Switching biologic treatments can enhance psoriasis disease control, but it is unclear if this is because of desensitization to the initial treatment or the introduction of newer, more effective treatments. To address this research gap, studies that swap between parallel treatment arms should be conducted to determine the most effective treatment strategy.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
Budget Impact of Intravenous Eptinezumab in the Prevention of Chronic Migraine Patients in United Arab Emirates () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2616;
Eptinezumab resulted in cost savings in non-drug medical expenses due to reduced frequency of migraine attacks, fewer adverse events, and lower productivity loss. Despite the upfront drug costs of eptinezumab, these were offset by the savings from reduced migraine management and productivity loss.
- Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Meta-Analysis of Lipid-Lowering Efficacy and Cardiovascular Safety of PCSK9i in Treating ACS () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2450;
In terms of safety, there was no statistically significant difference in the incidence of cardiovascular adverse events between the experimental and control groups. However, given the small number and quality variations among the included studies, the above conclusions still need to be confirmed by large-scale, high-quality randomized controlled trials.
- Nplate (romiplostim) / Amgen
Economic Evaluation of Using Romiplostim for Early Immune Thrombocytopenia in Qatar () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2360;
Early initiation of romiplostim in ITP is not only clinically effective, but also cost saving compared to late initiation. The budget impact analysis supported the economic outcomes, indicating potential healthcare savings.
- Livial (tibolone) / Organon, Prolia (denosumab) / Amgen
Utilization and Expenditure on Medicines for the Prevention and Treatment of Osteoporosis: A Changing Landscape () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2339;
This study highlights the changing landscape of osteoporosis prevention and treatment in Ireland, over a 13-year period. Further research into treatment adherence with these therapies is warranted, given an aging population and attendant increase in fractures with associated healthcare resource use.
- An Evaluation of Non-Randomized Evidence (NRE) Used in HTA Decision-Making: A Case Study Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2318;
These case studies illustrate that NRE can be a critical component in HTA and regulatory decision-making, particularly when RCTs are not feasible. NRE can provide robust evidence to support the efficacy and safety of treatments, facilitating access to innovative therapies for patients with high unmet medical needs.
- No Demand-Side Policies, No Expenditure Savings () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2309;
NRE can provide robust evidence to support the efficacy and safety of treatments, facilitating access to innovative therapies for patients with high unmet medical needs. METHODS : This study analyzed the trends of the originators
- Bavencio (avelumab) / EMD Serono, Blincyto (blinatumomab) / Astellas, Amgen, Alecensa (alectinib) / Roche
Synthetic Control Arms Data Driven by Artificial Intelligence: A Viable Alternative to Placebo Cohorts in Comparative Clinical Studies? () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2217;
P=N/A
They could also address ethical and recruitment challenges in placebo-controlled trials by enabling robust sample sizes in rare and severe disease studies. However, digital twins are in validation stages with preliminary results, and the use of RWE and historical data for SCAs has been accepted as supplementary evidence alongside placebo RCTs.
- Improving Access to Innovative Therapies for Rare Bleeding Disorders: Evidence From High Income Countries () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2176;
High costs often pose barriers, but PASs and cost-minimization measures can positively influence decisions. Continued HTA methods advancements, like CDA-AMC's "Time-Limited Reimbursement Recommendations", could enhance accessibility and affordability of these therapies, ensuring timely and effective treatment for patients with RBDs.
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
A Cost-Effectiveness Analysis of Erythropoietin Alfa Versus Darbepoetin Alfa in Chronic Kidney Disease Patients () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2113;
Continued HTA methods advancements, like CDA-AMC's "Time-Limited Reimbursement Recommendations", could enhance accessibility and affordability of these therapies, ensuring timely and effective treatment for patients with RBDs. Darbepoetin alfa emerges as a more cost-effective option for managing anemia in CKD patients compared to Erythropoietin alfa.
- Review of Real-World Evidence (RWE) in Marketing Authorization Applications (MAAs) Highlight Differences in Evidentiary Standards Among Regulatory and Health Technology Assessment (HTA) Bodies () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1931;
RWE supporting effectiveness in MAAs was accepted more frequently by FDA than EMA, while HTA review highlighted differing standards of RWE acceptability. Consideration should be given to these differences when generating RWE for regulatory decision-making and appraisals.
- Prolia (denosumab) / Amgen
Use of Not-Recommended Cancer Treatments Among Socio-Economically Disadvantaged Medicare Beneficiaries () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1823;
However, this finding was not consistent across all disadvantaged groups or by treatment. Our results suggest that targeted approaches depending on treatment would increase the effectiveness of efforts to reduce utilization of not-recommended cancer treatments.
- Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
An Update on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reimbursed Under a Managed Access Protocol in Ireland () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1756;
4 mmol/L (i.e. primary prevention cohort). When used in conjunction with health technology assessment, MAPs, an example of health technology management, enable access to new drug treatments for patients likely to derive most clinical benefit, while providing budgetary oversight and certainty for the payer.
- Tavneos (avacopan) / Amgen
Cost-Effectiveness of Avacopan for the Treatment of Granulomatosis with Polyangiitis or Microscopic Polyangiitis in Adult Patients in Austria () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1494;
This analysis wants to evaluate avacopan (AVA) in combination with either a rituximab (RTX) or cyclophosphamide (CYC) dosing regimen, compared to prednisolone plus RTX or CYC in adult patients with severe active GPA or MPA. In adult patients with this rare and severe active condition (AAV), Avacopan shows a good and affordable cost-effectiveness relationship from the Austrian payer perspective.
- Utilizing Generative AI Technology for Comprehensive HTA Report Analysis () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1493;
Primary and secondary endpoints varied: Cabozantinib focused on overall survival (OS) with PFS and ORR as secondary, while Atezolizumab plus Bevacizumab and Regorafenib emphasized OS and PFS with additional endpoints like ORR, TTP, DCR, and quality of life...All Generative-AI responses were validated by human-in-the-loop. CONCLUSIONS : Generative-AI technology can provide valuable insights and comprehensive analysis of HTA reports and makes navigating the complex landscape of global health technology assessments easy.
- A Systematic Review of Pharmacological Interventions for Hidradenitis Suppurativa: A Focus on Clinical Response, Quality of Life, and Safety () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1258;
The results of this review demonstrate the possibility of highly personalized treatment approaches for HS management, including adalimumab and povorcitinib. The optimization of HS care requires further research on long-term outcomes.
- Enbrel (etanercept) / Pfizer, Amgen, Cosentyx (secukinumab) / Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
Cost of Biologics in Patients Suffering From Psoriasis in Greece: A Retrospective Longitudinal Cohort Study () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1158;
The study highlights significant variability in biologic treatment costs for PsO, influenced by drug, persistence, and prior treatment history. These findings underscore the importance of balancing clinical efficacy and economic impact in treatment decisions for PsO, ensuring effective care while managing healthcare resources efficiently.
- Assessing the Use of Time-to-Death Utilities for Advanced NSCLC Treatments: An HTA Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1111;
TTD based utilities are not widely used in HTA submissions for aNSCLC. Use of TTD based over progression-based utility can impact ICER, independently from the treatment effect.
- Health Technology Assessment (HTA) of Respiratory Biologics: Highlighting the Differences in Value Assessment of Asthma Interventions Globally () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1105;
These results can guide evidence-generation strategies, aiding in reimbursement and optimizing outcomes for biologics in asthma. Funding : GSK (GSK ID 222239)
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Price Sensitivity and Uptake of Pharmaceuticals in Sweden and Finland: The Example of New Migraine Drugs () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1058;
Included CGRP-inhibitors, reimbursed in both countries in 2020, were: Aimovig, Ajovy and Emgality. Studied price differences of CGRP-inhibitors were not large enough to influence physicians
- The European Pricing Landscape for Targeted Therapies in Advanced or Metastatic Non-Small Cell Lung Cancer to Achieve Maximum Progression Free Survival () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1024;
Studied price differences of CGRP-inhibitors were not large enough to influence physicians Annual costs ranged from selpercatinib UK =
- Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1001;
Differences observed in DS extrapolations may result in substantially different predictions of treatment line distributions over time, and therefore calculation of the most cost-effective treatment sequences. Further research should be conducted into comparisons of overall DS for newer biologic therapies and compared against NICE submission model drug survival extrapolations, and methods for more accurate DS prediction from short-term trial data.
- Assessing the Suitability of Real-World Data for Indirect Treatment Comparison Using NICE's Data Suitability Assessment Tool (DataSAT) () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_894;
When incorporating RWE into the clinical evidence base, suitability of evidence, through use of quality assessment tools, in line with the NICE RWE framework should be considered to increase trust and acceptability of such evidence. Further steps for improving the acceptability in HTA through greater quality, provenance, relevance, and accessibility of RWE data is warranted.
- Tecartus (brexucabtagene autoleucel) / Gilead
Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in Greece () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_893;
We aimed to estimate its cost-effectiveness versus blinatumomab (BLIN), inotuzumab ozogamicin (INO), and salvage chemotherapy (CHEMO) for patients ?26 years in Greece. Considering the high unmet need in this patient population due to limited survival outcomes of existing therapeutic alternatives, BREXU-CEL provides a valuable and potentially cost-effective alternative to current treatments, deriving its value from incremental survival and health-related quality of life benefits.
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen, Amvuttra (vutrisiran) / Alnylam, Lytgobi (futibatinib) / Otsuka
Assessing the Impact of a First-to-Market Product on the Orphan Designation Status for Subsequent Products Across the EU4 () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_823;
However, manufacturers of second- and third-to-market products must consider factors such as the significant benefit and time of approval to successfully maintain its orphan designation status. Direct comparative data, indirect comparisons, and protocol assistance can aid in demonstrating benefit.
- Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Treatments for First-Line (1L) Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (GC/GEJ) in Adult Patients () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_769;
PD-1/PD-L1 inhibitors showed improved efficacy compared to chemotherapy for the treatment of 1L GC/GEJ; while other targeted therapies showed promise in certain biomarker-selected patients. Increasing availability of new agents may provide options to address unmet need.
- Biosimilars: The Key to Lowering Access Barriers to Omalizumab Across Europe () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_660;
The disparities highlighted in this study underscore the need for improvement in access to omalizumab across Europe. This study highlights the need for comprehensive policy reforms and the introduction of omalizumab biosimilar to ensure equitable access to omalizumab across Europe, enhancing patient care and potentially solving shortage issues and expanding treatment options for off-label indications su ch as urticarial vasculitis and food allergy.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Clinical Benefits of CDK 4/6 Inhibitors in HR+ HER2- Metastatic Breast Cancer: A Systematic Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_558;
There is no compelling evidence of the superiority of one CDK4/6 inhibitor over others. A preference for a specific drug within the class can only be made after conducting direct RCTs or accumulating sufficient RWE on the use of such drugs.
- Stivarga (regorafenib) / Bayer
Using Digital Tools for the Early Identification and Monitoring of Regorafenib-Associated Hand-Foot Skin Reactions in Real-Life Setting: The FACET Study () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_507;
When integrated into clinical care, these devices could enhance treatment compliance and improve potentially the benefit of regorafenib in mCRC patients. Detailed information on patients
- Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia in Algeria () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_354;
Blinatumomab was considered as the sole comparator: it was assumed that Blina had all the market in the base case, whilst InO and Blina covered half the market each in the alternative scenario. The introduction of InO is expected to generate savings on treatment and hospitalization costs while improving patient convenience by reducing duration of hospital stay.
- Quality of Life Impact of Adverse Events Associated With Systemic Therapies for Metastatic Colorectal Cancer Previously Treated With Standard Therapies and Biologics Across 13 Countries in Europe, North America, and Asia () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_136;
AE-associated utility decrement was double that of disease progression, highlighting the significant impact of AEs on QoL. Fruquintinib was associated with lower AE-associated QoL decrement versus regorafenib, T/T and T/T+bev for patients with mCRC previously treated with standard therapies and biologics.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Budget Impact of Tezepelumab for the Treatment of Severe Asthma in the Brazilian Private Healthcare System () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_95;
In Brazil, available medications include omalizumab for severe allergic asthma (SAA), mepolizumab and benralizumab for severe eosinophilic asthma (SEA), and dupilumab for T2-high asthma. The inclusion of tezepelumab led to significantly lower medical expenses, highlighting its dual clinical and cost-saving impact.
- | Vectibix (panitumumab) / Amgen
Journal, Metastases: Immuno-PET Imaging of EGFR with 64Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts. (Pubmed Central) - Nov 4, 2024
[64Cu]Cu-NOTA-panitumumab was successfully used for immuno-PET imaging of EGFR-expressing subcutaneous and metastatic NSCLC tumors. This result represents the basis for developing radiotheranostics for targeting EGFR in cancers and for selecting the right patients for the right treatment at the right time.
- | Nailike (olverembatinib) / Takeda
Journal: Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. (Pubmed Central) - Nov 4, 2024
A total of 45% of patients experienced mild hematological treatment-related adverse events (TRAEs). Olverembatinib-based treatment led to promising outcomes in de novo Ph?+?ALL patients but warranted further studies to investigate the best-combined strategy.
- | Journal, CAR T-Cell Therapy, IO biomarker: CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase. (Pubmed Central) - Nov 4, 2024
Olverembatinib-based treatment led to promising outcomes in de novo Ph?+?ALL patients but warranted further studies to investigate the best-combined strategy. He was treated with shortened acute lymphoblastic leukemia induction plus the tyrosine kinase inhibitor (TKI) imatinib followed by dasatinib...Multiple therapeutic approaches including ponatinib, blinatumomab, a 2nd HSCT from a different donor, donor lymphocyte infusions, and high-dose asciminib all resulted in subsequent relapse...In this situation, CD19-directed CAR-T cells (Kymriah
- || Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal: Teprotumumab Related Hearing Loss: A Large-Scale Analysis and Review of Voluntarily Reported Patient Complaints to the Food and Drug Administration (FDA). (Pubmed Central) - Nov 4, 2024
He was treated with shortened acute lymphoblastic leukemia induction plus the tyrosine kinase inhibitor (TKI) imatinib followed by dasatinib...Multiple therapeutic approaches including ponatinib, blinatumomab, a 2nd HSCT from a different donor, donor lymphocyte infusions, and high-dose asciminib all resulted in subsequent relapse...In this situation, CD19-directed CAR-T cells (Kymriah Patients treated with teprotumumab should receive warnings regarding the increased risk of hearing-related impairments and receive audiometry before, during, and after treatment.